Prostate cancer
INACTIVE ---Treatment decision-making in castration-resistant prostate cancer

Scott (58 years old)

Scott, a 58-year-old carpenter, has no major comorbidities. He was diagnosed with multiple bone metastatic PCa:

  • CT scan: prostatic enlargement, no sign of visceral metastases
  • PSA: 385 ng/ml
  • ISUP grade 3 [Gleason score: 4+3]
  • Asymptomatic but experiences fatigue

He was treated with ADT + 6 cycles of docetaxel. His PSA at 6 months was 2.1 ng/ml, ALP 31 U/l.

At 24 months post-ADT initiation:

  • Increase in PSA to 24 ng/ml in 8 months
  • Castrate testosterone level
  • Bone scan shows progression of bone metastases
  • CT scan shows 1 visceral metastasis (lung)
  • Bone pain: requires paracetamol
  • ECOG PS: 1

Treatment for mCRPC was started with abiraterone:

  • PSA dropped to 4.1 ng/ml
  • Bone metastases shrank by 20% (RECIST)

9 months after starting abiraterone:

  • PSA rise to 20 ng/ml, ALP to 185 U/l
  • Radiographic progression of lymph nodes and lung metastasis
  • ECOG PS: 1

 

Which treatment option would you choose for this patient?